Allogene Therapeutics, Inc.
ALLOHealthcare|Biotechnology|US
$1.04
-0.05 (-4.59%)
Tangible Book / Share
$1.13
Cash / Share
$0.85
Financials
Financial Snapshot
Market Cap
$359.3M
Enterprise Value
$398.1M
Revenue (TTM)
$4.6M
Net Income (TTM)
-$174.5M
Cash & Investments
$293.0M
Net Cash
$224.9M
Free Cash Flow (TTM)
-$108.8M
Operating CF (TTM)
-$108.6M
Debt/Equity
0.17
Cash Runway & Burn Rate
Cash on Hand
$293.0M
Quarterly Burn
$27.2M
Monthly Burn
$9.1M
Est. Runway
~10.8 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $721.4M | $530.5M | $827.9M | $457.3M | $517.3M | $448.7M | $292.5M | $250.2M | $293.0M | |
| Operating Cash Flow | $0.00 | -$44.7M | -$137.3M | -$115.1M | -$184.8M | -$220.5M | -$237.7M | -$200.3M | -$149.2M | -$108.6M | |
| Free Cash Flow | $0.00 | -$47.9M | -$188.1M | -$181.1M | -$206.3M | -$225.7M | -$239.2M | -$201.0M | -$149.6M | -$108.8M | |
| Capital Expenditure | $0.00 | -$3.2M | -$50.8M | -$66.0M | -$21.4M | -$5.2M | -$1.5M | -$694.0K | -$386.0K | -$184.0K | |
| Financing Cash Flow | $0.00 | $771.2M | $59.0M | $633.6M | $12.0M | $3.0M | $95.7M | $116.7M | $30.2M | $217.5M |
R&D Spending
R&D (TTM)
$133.3M
R&D Intensity
2872.6%
R&D Growth vs Prior
-11.2%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $114.1M | $156.0K | $95.0K | $22.0K | $0.00 | $4.6M | |
| R&D Expense | $0.00 | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | $150.2M | $133.3M | |
| R&D % of Revenue | — | — | — | — | 193.0% | 164350.6% | 255698.9% | 874086.4% | — | 2872.6% | |
| SG&A | $2.0K | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | $56.8M | $61.6M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $114.1M | $156.0K | $95.0K | $22.0K | $0.00 | $4.6M | |
| Cost of Revenue | $0.00 | $0.00 | $5.0M | $11.5M | $0.00 | $14.3M | $0.00 | $0.00 | $12.4M | $0.00 | |
| Gross Profit | $0.00 | -$1.5M | -$5.0M | -$11.5M | $114.1M | -$14.1M | $95.0K | $22.0K | -$12.4M | $4.6M | |
| R&D | $0.00 | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | $150.2M | $133.3M | |
| SG&A | $2.0K | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | $56.8M | $61.6M | |
| Operating Income | -$2.0K | -$192.8M | -$202.0M | -$258.2M | -$180.2M | -$335.5M | -$327.7M | -$273.2M | -$206.9M | -$190.2M | |
| Interest Expense | $0.00 | $3.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $181.0K | $1.1M | $577.0K | |
| Pretax Income | -$24.0K | -$211.6M | -$184.9M | -$250.2M | -$182.1M | -$340.4M | -$327.3M | -$257.1M | -$190.9M | -$174.5M | |
| Net Income | -$2.0K | -$211.5M | -$184.6M | -$250.2M | -$182.1M | -$340.4M | -$327.3M | -$257.6M | -$190.9M | -$174.5M | |
| EPS (Diluted) | -0.00 | -2.36 | -1.83 | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 | -0.63 | |
| EBITDA | $22.0K | -$206.8M | -$179.9M | -$242.6M | -$171.6M | -$326.1M | -$313.1M | -$243.3M | -$177.5M | -$169.4M | |
| Shares Out. (M) | 44.01 | 89.69 | 101.06 | 120.37 | 135.82 | 143.15 | 156.93 | 194.81 | 220.62 | 346.09 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $721.4M | $175.1M | $183.4M | $173.3M | $61.9M | $83.2M | $75.2M | $51.7M | $29.3M | |
| Short-Term Investments | $0.00 | $0.00 | $355.4M | $644.6M | $284.0M | $455.4M | $365.5M | $217.3M | $198.5M | $263.7M | |
| Total Current Assets | $0.00 | $468.0M | $544.6M | $845.1M | $471.3M | $528.8M | $459.1M | $303.4M | $257.7M | $299.8M | |
| Total Assets | $0.00 | $773.9M | $717.8M | $1.23B | $1.05B | $821.6M | $642.8M | $548.7M | $415.9M | $511.3M | |
| Total Current Liabilities | $2.0K | $29.5M | $33.1M | $94.3M | $47.9M | $53.7M | $37.1M | $35.5M | $32.5M | $38.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $68.0M | |
| Total Liabilities | $2.0K | $70.7M | $88.8M | $148.2M | $125.6M | $154.7M | $130.6M | $126.5M | $123.4M | $118.8M | |
| Stockholders' Equity | -$2.0K | $703.2M | $629.0M | $1.08B | $925.2M | $666.9M | $512.2M | $422.2M | $292.5M | $392.6M | |
| Retained Earnings | -$23.0K | -$211.5M | -$396.1M | -$646.3M | -$894.6M | -$1.23B | -$1.56B | -$1.82B | -$2.01B | -$2.15B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | -$44.7M | -$137.3M | -$115.1M | -$184.8M | -$220.5M | -$237.7M | -$200.3M | -$149.2M | -$108.6M | |
| Capital Expenditure | $0.00 | -$3.2M | -$50.8M | -$66.0M | -$21.4M | -$5.2M | -$1.5M | -$694.0K | -$386.0K | -$184.0K | |
| Free Cash Flow | $0.00 | -$47.9M | -$188.1M | -$181.1M | -$206.3M | -$225.7M | -$239.2M | -$201.0M | -$149.6M | -$108.8M | |
| Investing Cash Flow | $0.00 | -$632.8M | $164.1M | -$505.1M | $163.7M | $106.2M | $163.3M | $75.7M | $95.6M | -$117.4M | |
| Financing Cash Flow | $0.00 | $771.2M | $59.0M | $633.6M | $12.0M | $3.0M | $95.7M | $116.7M | $30.2M | $217.5M | |
| Issuance of Stock | $0.00 | $343.7M | $54.2M | $621.9M | $12.0M | $3.0M | $91.1M | $114.4M | $23.2M | $28.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | |
| Net Debt Issuance | $0.00 | $116.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $18.6M | $46.1M | $65.3M | $80.8M | $83.6M | $66.0M | $51.7M | $37.6M | $35.9M | |
| Net Change in Cash | $0.00 | $93.7M | $85.7M | $13.4M | -$9.2M | -$111.4M | $21.3M | -$7.9M | -$23.5M | -$8.5M |
Dilution Tracker
Shares outstanding grew 83.3% over 5 years — significant dilution
Shares Outstanding
345M
5-Year Share Growth
+83.3%
Stock Issuance (TTM)
$28.5M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 44.01 | 89.69 | 101.06 | 120.37 | 135.82 | 143.15 | 156.93 | 194.81 | 220.62 | 346.09 | |
| Change vs Prior % | — | 103.8% | 12.7% | 19.1% | 12.8% | 5.4% | 9.6% | 24.1% | 13.2% | 56.9% | |
| Stock Issuance | $0.00 | $343.7M | $54.2M | $621.9M | $12.0M | $3.0M | $91.1M | $114.4M | $23.2M | $28.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | |
| Stock Based Comp. | $0.00 | $18.6M | $46.1M | $65.3M | $80.8M | $83.6M | $66.0M | $51.7M | $37.6M | $35.9M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | 100.0% | -9063.5% | 100.0% | 100.0% | — | 100.0% | |
| Operating Margin % | — | — | — | — | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — | -4099.3% | |
| Net Margin % | — | — | — | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — | -3760.0% | |
| EBITDA Margin % | — | — | — | — | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — | -3650.0% | |
| FCF Margin % | — | — | — | — | -180.8% | -144685.9% | -251841.1% | -913609.1% | — | -2345.0% | |
| ROE % | 100.0% | -30.1% | -29.3% | -23.2% | -19.7% | -51.0% | -63.9% | -61.0% | -65.3% | -49.8% | |
| ROA % | 0.0% | -27.3% | -25.7% | -20.4% | -17.3% | -41.4% | -50.9% | -46.9% | -45.9% | -34.1% | |
| ROIC % | 0.0% | -25.9% | -29.4% | -22.7% | -17.9% | -43.4% | -53.5% | -52.5% | -52.8% | -40.2% | |
| R&D / Revenue % | — | — | — | — | 193.0% | 164350.6% | 255698.9% | 874086.4% | — | 2872.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -99.9% | -39.1% | -76.8% | -100.0% | |
| Gross Profit | 0.0% | 0.0% | -235.1% | -129.6% | 1088.6% | -112.4% | 100.7% | -76.8% | -56277.3% | |
| Operating Income | 0.0% | -9642000.0% | -4.8% | -27.8% | 30.2% | -86.2% | 2.3% | 16.6% | 24.3% | |
| Net Income | 0.0% | -10575150.0% | 12.7% | -35.6% | 27.2% | -87.0% | 3.9% | 21.3% | 25.9% | |
| EPS (Diluted) | 0.0% | -5193230.5% | 22.5% | -13.7% | 35.6% | -77.6% | 12.2% | 36.8% | 34.1% | |
| Operating Cash Flow | 0.0% | 0.0% | -207.6% | 16.2% | -60.6% | -19.3% | -7.8% | 15.7% | 25.5% | |
| Free Cash Flow | 0.0% | 0.0% | -292.9% | 3.8% | -13.9% | -9.4% | -6.0% | 16.0% | 25.6% | |
| R&D Expense | 0.0% | 0.0% | -4.8% | 33.5% | 14.1% | 16.4% | -5.3% | -20.8% | -21.9% | |
| SG&A Expense | 0.0% | 2049000.0% | 40.2% | 13.5% | 13.6% | 7.0% | -9.6% | -9.0% | -12.9% | |
| Total Assets | 0.0% | 0.0% | -7.2% | 71.1% | -14.4% | -21.8% | -21.8% | -14.6% | -24.2% | |
| Book Value / Share | 0.0% | 17252382.0% | -20.6% | 44.1% | -24.1% | -31.6% | -29.9% | -33.6% | -38.8% | |
| Debt | 0.0% | 0.0% | 53.9% | 1.4% | 36.0% | 38.3% | -5.9% | -4.6% | -8.3% | |
| Diluted Shares | 0.0% | 103.8% | 12.7% | 19.1% | 12.8% | 5.4% | 9.6% | 24.1% | 13.2% |
Valuation
P/E (TTM)At Loss
P/S77.44
10Y Low / Med / High17.76 / 5771.76 / 18861.34
P/B0.92
10Y Low / Med / High0.98 / 2.19 / 4.17
EV/EBITDAAt Loss
EV/Revenue85.79
10Y Low / Med / High16.88 / 6023.17 / 19567.62
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$1.13
Net Current Assets / Share
$0.52
Graham Net-Net
$0.50
Cash / Share
$0.85
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -550140.95 | -11.41 | -14.20 | -12.13 | -11.13 | -2.64 | -1.54 | -1.61 | -1.57 | -1.65 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 17.76 | 5771.76 | 5302.65 | 18861.34 | 0.00 | 77.44 | |
| P/B Ratio | -550140.92 | 3.43 | 4.17 | 2.81 | 2.19 | 1.35 | 0.98 | 0.98 | 1.03 | 0.92 | |
| EV/EBITDA | 50012.81 | -8.36 | -13.92 | -11.99 | -11.23 | -2.88 | -1.65 | -1.77 | -1.88 | -2.35 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 16.88 | 6023.17 | 5428.61 | 19567.62 | 0.00 | 85.79 |
Analyst Estimates & Quality
Altman Z-Score
-4.59
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.8M | $13.4M | $84.6M |
| Net Income | -$133.8M | -$141.3M | -$112.6M |
| EPS | $-0.60 | $-0.64 | $-0.55 |
| # Analysts (EPS) | 5 | 6 | 10 |
Revenue Segments
By Product
| Segment | 2024 | 2025 |
|---|---|---|
| License | $4.6M | $4.6M |